First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $969M — +93.0% growth in a single year.
Why Revenue Could Explode
1Attruby quarterly prescription data and revenue trajectory - market expects 15,000-20,000 patients on therapy at steady state vs. current early launch phase
2Clinical trial readouts from pipeline programs, particularly infigratinib Phase 3 data in achondroplasia (pediatric growth disorder) and BBP-418 data in muscular dystrophy
3Competitive dynamics with Pfizer's Vyndaqel/Vyndamax franchise - market share capture, head-to-head trial results, and physician adoption patterns
4Cash runway updates and path to profitability - company had $1.1B cash at recent reporting with $500M annual burn rate, implying 2+ years runway
5FDA regulatory decisions on pipeline assets and potential label expansions for Attruby into earlier-stage ATTR-CM or polyneuropathy indications
growth - BridgeBio attracts growth-oriented biotech investors focused on commercial execution of newly launched rare disease therapies…
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of future cash flows…
Watch on earnings: Attruby weekly prescription data from IQVIA/Symphony tracking services - leading indicator of revenue trends, ATTR-CM patient diagnosis rates and genetic testing volumes - market expansion driver beyond current 30-40% diagnosed population, Pfizer Vyndaqel franchise quarterly sales and market share trends - competitive benchmark.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $969M to $1.6B as attruby quarterly prescription data and revenue trajectory - market expects 15,000-20.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.